Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved

Drug Metabolism and Disposition

Volumn 32, Issue 6, 2004, Pages 639-646

  He, Kan ^a,d   Talaat, Rasmy E ^a   Pool, William F ^a   Reily, Michael D ^a   Reed, Jessica E ^a   Bridges, Alexander J ^a,b   Woolf, Thomas F ^a,c  

^a PFIZER INC   (United States)

^b QuatRx Pharmaceuticals Company   (United States)

^c ELAN PHARMACEUTICALS   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 GLUTATHIONYL 5 [4 (6 HYDROXY 2,5,7,8 TETRAMETHYLCHROMAN 2 YLMETHOXY)BENZYL]THIAZOLIDINE 2,4 DIONE; BETA NAPHTHOFLAVONE; C5 THIAZOLIDINEDIONE; CATION; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; GLUTATHIONE; GLUTATHIONE ETHYL ESTER; KETOCONAZOLE; MICROSOME PROTEIN; PHENOBARBITAL; PROTEIN; PYRIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFONIUM DERIVATIVE; SULFOXIDE; SULFUR CATION RADICAL; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUMMERER REACTION; RAT;

ANIMALS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CELLS, CULTURED; CHROMANS; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; GLUTATHIONE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, INBRED F344; THIAZOLIDINEDIONES;

ANIMALIA;

EID: 2442707819     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.6.639     Document Type: Article

References (27)

1. Bae MA and Song BJ (2003) Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63:401-408.
2. Chan WK, Sui Z, and Ortiz de Montellano PR (1993) Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol 6:38-45.
3. Correia MA (1995) Rat and human liver cytochromes P450: substrate and inhibitor specificities and functional markers, in: Cytochrome P450 (Ortiz de Montellano PR ed), pp 607-630, Plenum Press, New York.
4. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
5. Gillam EM, Baba T, Kim BR, Ohmori S, and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131.
6. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, and Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259.
7. He K, Woolf TF, and Hollenberg PF (1999) Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 288:791-797.
8. House HO (1972) Modern Synthetic Reactions. The Benjamin/Cummings Publishing Company, Reading, MA.
9. Kaplowitz N, Aw TY, Simon FR, and Stolz A (1986) Drug-induced hepatotoxicity [clinical conference]. Ann Intern Med 104:826-839.
10. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70.
11. Kawai K, Kawasaki Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, et al. (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim-Forsch 47:356-368.
12. Lee WM, Speeg KV, and Bay MK (1995) Drug-induced hepatotoxicity. N Engl J Med 333: 1118-1127.
13. Leeder JS (1998) Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39 (Suppl 7):S8-S16.
14. Lehmann JM, Moore LB, Smith Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
15. Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, and Koup JR (1997) Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 37:1038-1047.
16. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, and Tamai I (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32:291-294.
17. Omura T and Sato R (1964) The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
18. Pessayre D and Larrey D (1988) Acute and chronic drug-induced hepatitis. Bailliere's Clin Gastroenterol 2:385-422.
19. Prabhu S, Fackett A, Lloyd S, McClellan HA, Terrell CM, Silber PM, and Li AP (2002) Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem-Biol Interact 142:83-97.
20. Saltiel AR and Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669.
21. Speeg KV and Bay MK (1995) Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am 24:1047-1064.
22. Strobel HW and Dignam JD (1978) Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol 52:89-96.
23. Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, and Park BK (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965-974.
24. Valadon P, Dansette PM, Girault JP, Amar C, and Mansuy D (1996) Thiophene sulfoxides as reactive metabolites: formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo. Chem Res Toxicol 9:1403-1413.
25. Walsh CT (1984) Suicide substrates, mechanism-based enzyme inactivators: recent developments. Annu Rev Biochem 53:493-535.
26. Watkins PB and Whitcomb RW (1998) Hepatic dysfunction associated with tooglitazone [letter; comment]. N Engl J Med 338:916-917.
27. Waxman DJ and Walsh C (1982) Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. J Biol Chem 257:10446-10457.